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access article under the CC BY-NC-NDSummary Background/objective: Oxidative stress plays an important role in osteoarthritis
(OA), causing inflammation and matrix degradation in joints. Previous studies have shown that
antioxidants such as quercetin and vitamin C are potential candidates for treating OA. We
aimed to determine whether a formulation of quercetin and vitamin C, together with an iron
chelator, could retard OA progression in a post-traumatic OA rat model.
Methods: Twelve rats received anterior cruciate ligament transection for OA induction. At 20
weeks postoperation, weekly intra-articular injection of 50 mL of either saline or a formulation
of quercetin dehydrate, sodium-L-ascorbate, and deferoxamine mesylate was given consecu-
tively for 4 weeks (nZ 5). Gait analysis was performed at pretreatment, and at 1 week and 5
weeks post-treatment. Microcomputed tomography scanning and histological scoring were per-
formed at 5 weeks post-treatment.
Results: Gait analysis showed that intra-articular injections of antioxidant formulation did not
improve pain-associated Limb Idleness Index over time (pZ 0.449, Friedman test). However,
at 5 weeks post-treatment, the treatment group exhibited a significantly lower Limb Idleness
Index than the control group (pZ 0.047, ManneWhitney U test). At 5 weeks post-treatment,
microcomputed tomography analysis revealed that there was no difference in any parameter
between the treatment and control groups (p> 0.05, Student t test). Severe OA histopatholog-
ical changes were found in both groups. The Osteoarthritis Research Society Internationalof Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince
treet, Shatin, New Territories, Hong Kong Special Administrative Region.
.edu.hk (K.-M. Chan).
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26 Y.-C. Cheuk et al.scores of the treatment and control groups were 20 (range, 20e26) and 20 (range, 9e26),
respectively (pZ 0.382, ManneWhitney U test).
Conclusion: Intra-articular injection of an antioxidant formulation containing quercetin,
vitamin C, and deferoxamine did not retard OA progression in advanced-stage OA. Future
studies should aim to determine whether giving antioxidants in early OA, with prolonged drug
retention, would be effective in retarding OA progression.
ª 2016 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking
Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA), a degenerative joint disease, affects
the whole joint, causing pain, deformity, and loss of
function. According to the World Health Organization, it is
estimated that 9.6% of men and 18.0% of women aged over
60 years have symptomatic OA (http://www.who.int/chp/
topics/rheumatic/en/). Currently, there is no promising
treatment for OA. Increasing evidence showed that
oxidative stress resulting from excessive production of
reactive oxygen species (ROS) plays a role in the patho-
genesis of OA [1]. Clinical studies demonstrated that
oxidative stress was present in OA patients, where an
abnormal antioxidant level was observed in the synovial
fluid and serum of patients with primary and secondary OA
[2,3]. Oxidative stress triggers inflammatory responses [4],
induces extracellular matrix degradation, and inhibits
matrix synthesis [5], and eventually leads to OA changes.
ROS pathways are becoming one of the new treatment
targets for OA [6]. To counteract the elevated oxidative
stress, antioxidant therapy has been developed to rein-
force the cellular antioxidant status. These include anti-
oxidant supplements, dietary polyphenols, free radical
scavengers, nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase inhibitors, and inducible nitric oxide
synthase (iNOS) inhibitors [7]. Combining multiple anti-
oxidants that have different actions may be a better
approach to tackle oxidative stress in OA. Of these,
quercetin (Que) and vitamin C are two well-known anti-
oxidants that possess potential beneficial effects on OA.
Que, a polyphenolic bioflavonoid found ubiquitously in
food of plant origin, exhibits a wide range of effects on
biological systems, particularly on anti-inflammation and
antioxidation [8]. In vivo studies demonstrated that Que
reduced the expression of inflammatory markers, restored
antioxidant defence, subsided OA clinical signs, and
delayed arthritis in rats with adjuvant arthritis [9,10]. The
elevated inflammation in post-traumatic OA rats had also
been reversed with Que treatment [11]. Furthermore,
clinical studies on a dietary supplement consisting of Que
had also shown favourable effects on OA-associated symp-
toms [12,13].
Another potent antioxidant, vitamin C (ascorbic acid),
has a broad spectrum of antioxidative activities, owing to
its ability to scavenge numerous ROS [14]. It also acts as a
cofactor for numerous biochemical reactions and is essen-
tial for collagen biosynthesis [15]. A preclinical study on
surgically induced OA in guinea pigs [16] and anepidemiological study on OA patients [17], both suggested
that high dietary intake of vitamin C reduced the risk of
cartilage loss and delayed disease progression. In addition,
vitamin C level in joint fluids was significantly lower in
patients with severe OA [3].
However, vitamin C can exhibit pro-oxidant activities,
particularly in the presence of iron [18,19]. Iron level in the
serum [20] and synovial fluid [21] of patients with OA was
found to be elevated. It has been proposed that the high
level of iron increases ROS, which leads to an upregulation
of matrix metalloproteinases, thereby causing cartilage
damage after joint trauma [22]. Iron chelators, such as
deferoxamine (also known as desferrioxamine; DFO) and
deferiprone, are commonly used chelating agents for
removing excess iron from the body [23]. It can relieve
oxidative stress in arthritic joint by inhibiting the iron-
catalysed formation of destructive oxygen metabolites
[24]. An animal study had also demonstrated that intra-
articular (IA) injections of DFO reduce blood-induced knee
joint damage [25].
Since Que, vitamin C, and DFO exhibit different
mechanisms, we proposed to inject them as a formulation
to treat OA knee in a post-traumatic rat model. In a pre-
vious pilot study on repeated IA injections of this formu-
lation in OA rats, we observed a reduction in pain-
associated limb idleness and less severe histopatholog-
ical changes at 4 months post OA induction (Supplemen-
tary materials). These suggested that this antioxidant
formulation may possess both symptom and disease-
modifying potential. In this study, the same formulation
was investigated to further prove its effectiveness in pain
modulation and delaying degenerative changes in both the
articular cartilage and the subchondral bone at a late
stage OA in the knee.Materials and methods
Anterior cruciate ligament transection for
induction of post-traumatic OA
Animal experiments were approved by the Animal Experi-
mentation Ethics Committee in The Chinese University of
Hong Kong (Ref. no.: 11/008/DRG). Twelve female Sprague-
Dawley rats at 12 weeks of age (average body weight
229.1 13.2 g) underwent unilateral anterior cruciate lig-
ament transection of the right knee for OA induction [26].
Under general anaesthesia, a medial parapatellar incision
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knee joint; the anterior cruciate ligament was transected
with microscissors. An anterior drawer test was performed
to ensure successful transection. After patella relocation,
joint capsule and skin were closed sequentially. Rats were
allowed free cage activity after the operation.
IA injection of Que formulation
At Week 20 postoperation, IA injections were given once a
week, for 4 consecutive weeks. Antioxidant formulation
containing 30 mg/mL sodium-L-ascorbate (Cat no.: A4034;
Sigma-Aldrich, St. Louis, MO, USA), 1 mg/mL Que dihy-
drate (Cat no.: Q0125; Sigma-Aldrich), and 200 mg/mL
deferoxamine mesylate (Cat no.: D9533; Sigma-Aldrich)
was freshly prepared in sterile distilled water as a sus-
pension. Under general anaesthesia and with the knee
flexed, 50 mL antioxidant formulation or 0.9% saline was
injected slowly into the operated knee of the rats through
the transpatellar tendon approach using a 50 mL syringe
with a 26G removable needle (Hamilton Company, Reno,
NV, USA).
Functional assessment by gait analysis
At pretreatment (20 weeks postoperation), and 1 week and
5 weeks post-treatment, gait analysis was performed using
Catwalk XT 9.0 system (Noldus Information Technology,
Wageningen, The Netherlands). Rats were allowed to walk
voluntarily back and forth along a glass walkway. Runs with
<30% variation in the speed were recorded as compliant
runs and were used for analysis. Gait parameters, including
Limb Idleness Index (LII), to detect OA-associated pain
were calculated [26].
Microcomputed tomography analysis
At 5 weeks post-treatment, rats were sacrificed by an
overdose of pentobarbital. The whole knee joint segment
was harvested for microcomputed tomography (mCT) scan-
ning (VivaCT40; Scanco Medical AG, Bru¨ttisellen,
Switzerland) at a resolution of 35 mm. Analysis was per-
formed by the built-in software as described previously
[26]. In brief, a rectangular volume of interest with di-
mensions of 2 mm (L) 1 mm (W) 0.5 mm (D) was put in
the subchondral bone at the medial and lateral tibial
epiphysis, where OA-related bone alterations were found
previously [6]. Trabecular indices including bone volume/
tissue volume, connectivity density, trabecular thickness,
trabecular number, and trabecular separation were
determined.
Histological scoring
Knee samples were fixed in 10% buffered formalin solution
overnight, decalcified in 9% formic acid for 4 weeks, and
paraffin embedded. Five micron frontal sections were
prepared for routine hematoxylin and eosin staining, and
toluidine blue staining. The Osteoarthritis Research Society
International (OARSI) Osteoarthritis Cartilage Histopathol-
ogy Assessment System (OOCHAS system) was used toevaluate the severity of OA in the samples as a combined
score of six grades of severity four stages (extent of
affected regions) by two raters (YC Cheuk and SW Mok) [27].
Statistical analysis
Statistical analysis was performed using SPSS (version 20.0
SPSS Inc., Chicago, IL, USA). All parametric tests were
performed after checking for normal distribution with Kol-
mogoroveSmirov test; otherwise, a nonparametric equiva-
lence was used. Friedman test was used to compare gait
data with respect to temporal changes. To compare mCT
data, and histological scoring between the control and
treatment groups, Student t test or ManneWhitney U test
was performed according to the normality and the nature
of the data (continuous vs. ordinal data). Inter-rater reli-
ability of histological scoring between two raters was
evaluated by calculation of the intraclass correlation co-
efficient. All statistical significance was determined at
p< 0.05.
Results
Among the 12 rats, the foot of a rat was trapped in the cage
at 10 weeks postoperation and only gait data at preopera-
tion were collected. In the treatment group, one rat died at
Week 27 postoperation (4 weeks after the 4th IA injection)
of unknown reasons. These two rats were excluded from
data analysis. The total number of rats that were used for
data analysis was 5 in each group.
Gait analysis for pain detection
Repeated IA injections of the antioxidant formulation did
not lead to improvement in pain-associated LII (pZ 0.449,
Friedman test). At 5 weeks post-treatment, the treatment
group exhibited a significantly lower LII than the control
group (pZ 0.047, ManneWhitney U test). However, at 1
week post-treatment, no significant difference was detec-
ted between the control and treatment groups (Figure 1).
Micro-CT analysis for microarchitectural changes in
subchondral bone
At 5 weeks post-treatment (28 weeks postoperation),
within the region of interest (ROI) in the tibia epiphysis, at
either medial or lateral compartment, there was no sig-
nificant difference in all mCT parameters between the
control and treatment groups (p> 0.05, Student t test)
(Table 1). However, in the treatment group, there was a
significantly higher trabecular thickness and bone mineral
density in the medial compartment as compared with the
lateral compartment (pZ 0.019 and pZ 0.010, respec-
tively; paired t test). No significant difference was
observed within the control group.
Histological scoring
The intraclass correlation coefficient of histological scores
between two raters was 0.975, indicating good inter-rater
Figure 1 Gait analysis of ACLT rats at pretreatment, and 1
week and 5 weeks post-treatment with either saline or an
antioxidant formulation. The values are presented as the dif-
ference in LII compared with the pretreatment level. An in-
crease in the LII indicates pain-associated gait changes. No
significant difference was detected after antioxidant treat-
ment (pZ 0.449, Friedman test). At 5 weeks post-treatment,
the treatment group exhibited a significantly lower LII than
the control group (pZ 0.047, ManneWhitney U test). ACLT -
Z anterior cruciate ligament transection; LIIZ Limb Idleness
Index.
28 Y.-C. Cheuk et al.reliability. The median maximum Osteoarthritis Research
Society International (OARSI) scores of the operated knee
in the treatment and control groups were 20 (range
20e26) and 20 (range 9e26), respectively (pZ 0.382,Table 1 Results of mCT measurements and OARSI scores in ACL t
postoperation).
Parameter (unit) Side Saline group
Bone mineral density (mg HA/ccm) Medial 815.90 21
Lateral 791.92 24
Bone volume/tissue volume (1) Medial 0.52 0.10
Lateral 0.42 0.08
Trabecular number (1/mm) Medial 8.14 0.47
Lateral 8.44 0.39
Trabecular thickness (mm) Medial 0.11 0.01
Lateral 0.09 0.01
Trabecular separation (mm) Medial 0.13 0.02
Lateral 0.14 0.01
Connectivity density (1/mm3) Medial 60.86 11.8
Lateral 82.70 17.8
Maximum OARSI score Operated 20 (9e26)
Data are presented as mean SD for mCT data and median (range) fo
mCT measurement, while those from ManneWhitney test are shown f
ACLZ anterior cruciate ligament; mCTZmicrocomputed tomogr
SDZ standard deviation.ManneWhitney U test). The most pathological site in both
groups was the medial tibia. Regardless of treatments, at
28 weeks postoperation (5 weeks post-treatment), the rat
knees showed complete cartilage erosion accompanied by
subchondral bone remodelling in the posterior compart-
ment of medial tibial plateau (Figure 2).
Discussion
The major limitation of the current study is its small sam-
ple size with a large within-group variation in the key
outcome measures, which largely affects the detectable
effect size. For structural assessments such as mCT mea-
surement and OARSI scores, the between-group differences
were too small to have a practical significance, with the
exception of connectivity density, which was shown to in-
crease with OA development [26]. The observed effect size
(based on t test) of antioxidant treatment on the connec-
tivity density is 0.6045, with an observed power of 13%. It
implies that 50 rats per group will be needed to detect this
difference with a power of 85%, which is not possible for
most animal studies. By contrast, the observed between-
group difference in LII was statistically significant with an
effect size of 1.82 and an observed power of 72%. It still
indicates the potential of the current antioxidant formu-
lation to treat OA even with a small-scale study. These
preliminary findings may support further investigation with
a larger sample size and encourage studies on dose
response, drug formulation, or mechanisms of the treat-
ment effects. Other limitations include a lack of treatment
groups with individual drugs and a lack of a positive drug
group. Moreover, the serum or tissue level of oxidative
stress was not measured.
Apart from conservative therapy, pharmacological
therapy includes oral nonsteroidal anti-inflammatory
drugs and Food and Drug Administration-approved IA in-
jectables such as analgesics, corticosteroids, and hyalur-
onates [28]. Systematic reviews suggested that someransected rat knees at 5 weeks post-treatment (i.e., 28 weeks
(nZ 5) Antioxidant formulation group (nZ 5) p
.31 828.41 29.45 0.464
.09 793.94 34.62 0.917
0.51 0.10 0.894
0.48 0.13 0.416
8.02 0.27 0.639
8.19 0.39 0.340
0.12 0.03 0.418
0.10 0.02 0.518
0.13 0.01 0.927
0.13 0.02 0.278
4 47.75 28.29 0.367
9 78.39 20.52 0.733
20 (20e26) 0.382
r OARSI score. The p values from Student t test are shown for the
or OARSI scores.
aphy; OARSIZOsteoarthritis Research Society International;
Figure 2 Bone microarchitecture and histology of rat knees at 5 weeks post-treatment with either (A, C, and E) saline or (B, D,
and F) antioxidant formulation. (A and B) Coronal view of mCT scanned rat knees. (CeF) Coronal view of toluidine blue-stained rat
knees at optical magnifications (C and D) 12.5 and (E and F) 50. Figures 2E and 2F represent high-power images of the region of
interest marked in Figures 2C and 2D. Representative image from each treatment group was selected from the sample with a group
median of the maximum OARSI scores. The OA grade and stage of the sample is marked in Figures 2E and 2F in the most pathological
compartment. In both groups, severe osteoarthritic changes with cartilage erosion and reparative fibrocartilage were present in
the medial tibial plateau, with an extent of >50% of cartilage surface. mCTZmicrocomputed tomography; OAZ osteoarthritis;
OARSIZ Osteoarthritis Research Society International.
Antioxidant formulation for osteoarthritis 29pharmaceuticals, particularly those administered intra-
articularly, are efficacious in reducing pain but associ-
ated with side effects. Currently, there is still a lack of
evidence supporting that any of the clinically used
treatments can achieve promising disease-modifying ef-
fects [29,30]. Our antioxidant formulation aimed to
counteract oxidative stress with naturally occurring anti-
oxidants, which possess fewer side effects.
Our results showed that repeated IA injections (started
from Week 20 postoperation) of the antioxidant formula-
tion containing Que, vitamin C, and DFO did not lead to
improvement in pain-associated LII (pZ 0.449, Friedman
test), OARSI score (pZ 0.382, ManneWhitney U test), andvarious mCT measurements. However, a significant differ-
ence in LII between the antioxidant formulation treatment
and saline control was observed at 5 weeks after treat-
ment. This suggests that an antioxidant formulation treat-
ment may slow down OA progression towards asymmetric
gait, although the current data did not show any symptom-
modifying (gait) or disease-modifying (histology) effects. In
our pilot study (Supplementary data), the antioxidant
formulation was given at an earlier time point (Week 16
postoperation), which was able to reduce limb idleness at
Week 28 significantly with less severe histopathological
changes. It is possible that this antioxidant treatment was
effective in retarding the development of OA only at early
30 Y.-C. Cheuk et al.stages (Week 16 postoperation), but not at an advanced
stage (week 20 postoperation).
In our pilot study, we also tested the effects of antiox-
idant formulation in the sham control in order to check
whether the treatment effect was specific to OA. We
observed the potential treatment effects on anterior cru-
ciate ligament transection rats only; thus, the antioxidant
formulation was not likely to target only the surgical
wound, which may also affect the measurement of pain-
associated walking gait. As repeated injections may cause
irritations to the knee and hence affect the gait analysis,
larger variations in LII were observed at 1 week after
treatment. It is thus difficult to evaluate the immediate
pain relief. In the present study, severe cartilage degen-
eration was observed in both the control and the treatment
group, but an increase in gait asymmetry after treatment
was observed only in the control group. It suggested that an
antioxidant formulation could not reverse existing osteo-
arthritic changes, but it might modulate nociceptive stimuli
associated with advanced OA. Previous studies showed that
antioxidants exerted chondroprotective effects with
respect to biochemical or histological outcome measures
[7], but assessments on painful responses were seldom
included. In addition, most of these studies administered
antioxidant treatments at an early stage of OA in the animal
model [11,16]. It implies that antioxidants may work only as
a dietary supplement to retard OA progression at early
stages, when symptoms and signs are not overt to call for
medication. The negative results of the present study also
support that antioxidant treatment at advanced stage of OA
may not be effective. Clinical use of antioxidant treatment
for OA patients is thus limited.
Apart from the time of application, the duration and
frequency of treatment will also affect the treatment
outcomes. IA injections of other Que formulation were re-
ported to show beneficial effects with more frequent in-
jections (2 injections per week for 4 weeks) [31]. Due to a
high clearance rate of biomolecules in the IA joint [32],
repeated and frequent injections are necessary. The
negative results observed in the current study may be
owing to the insufficient drug delivery to the joint, with the
four weekly injections. However, more IA injections will
cause repeated trauma to joints, which is not favourable
for examining the treatment effects. Thus, the use of
controlled delivery systems would help reduce the number
of injections and sustain the bioavailability of antioxidants
in osteoarthritic joints, which will be a future direction for
antioxidant treatment for OA.Conflicts of interest
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